CN114588226A - 一种治疗骨折的中药组合物及其制备方法 - Google Patents
一种治疗骨折的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN114588226A CN114588226A CN202210273655.0A CN202210273655A CN114588226A CN 114588226 A CN114588226 A CN 114588226A CN 202210273655 A CN202210273655 A CN 202210273655A CN 114588226 A CN114588226 A CN 114588226A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- ethanol
- powder
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 45
- 208000010392 Bone Fractures Diseases 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 34
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 24
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 24
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 22
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 22
- 239000006187 pill Substances 0.000 claims abstract description 13
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 12
- 239000009136 dragon's blood Substances 0.000 claims abstract description 12
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 11
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 11
- 240000004824 Trimezia steyermarkii Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 85
- 239000000843 powder Substances 0.000 claims description 65
- 241000180649 Panax notoginseng Species 0.000 claims description 38
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 25
- 238000001914 filtration Methods 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 16
- 238000000227 grinding Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 239000003463 adsorbent Substances 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000000049 pigment Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 241000218176 Corydalis Species 0.000 claims description 7
- 241000123589 Dipsacus Species 0.000 claims description 7
- 241001489978 Eupolyphaga Species 0.000 claims description 6
- 210000002435 tendon Anatomy 0.000 claims description 6
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 4
- 240000007890 Leonurus cardiaca Species 0.000 claims description 4
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 33
- 230000036407 pain Effects 0.000 abstract description 33
- 230000035876 healing Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- 206010017076 Fracture Diseases 0.000 description 21
- 230000001737 promoting effect Effects 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 230000017531 blood circulation Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 208000014674 injury Diseases 0.000 description 12
- 230000008736 traumatic injury Effects 0.000 description 12
- 230000008961 swelling Effects 0.000 description 11
- 244000186071 dragons blood palm Species 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 229940119485 safflower extract Drugs 0.000 description 8
- 241000628997 Flos Species 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000004089 microcirculation Effects 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 5
- 210000001624 hip Anatomy 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- UCZJPQIEFFTIEV-UHFFFAOYSA-N 5-methoxy-6-methyl-2-phenylchromen-7-one Chemical compound C=1C=C2C(OC)=C(C)C(=O)C=C2OC=1C1=CC=CC=C1 UCZJPQIEFFTIEV-UHFFFAOYSA-N 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 244000153234 Hibiscus abelmoschus Species 0.000 description 3
- 241001416180 Moschidae Species 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 208000021945 Tendon injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 239000009286 sanguis draxonis Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000131329 Carabidae Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000244987 Daiswa polyphylla Species 0.000 description 2
- 241001050741 Dipsacus asperoides Species 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- -1 veronicin Chemical compound 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 description 1
- BDHQMRXFDYJGII-UEBIAWITSA-N 24-methylenecycloartanol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@@]3(C)[C@@H]1CC2 BDHQMRXFDYJGII-UEBIAWITSA-N 0.000 description 1
- KKSCKZFKHNHGEO-UHFFFAOYSA-N 24-methylenecycloartanol Natural products CC(CCC(=C)C(C)(C)O)C1CCC2C3CCC4C(C)(C)C(O)CCC45CC35CCC12C KKSCKZFKHNHGEO-UHFFFAOYSA-N 0.000 description 1
- BJZVHTWNCLKZGN-SPQNPFHSSA-N 24-methylidenecycloartanol Natural products CC(C)C(=C)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C BJZVHTWNCLKZGN-SPQNPFHSSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001522633 Betula utilis subsp. albosinensis Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 239000008830 Carthamus tinctorius Honghua extract Substances 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 240000000425 Chaenomeles speciosa Species 0.000 description 1
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 235000015533 Prunus davidiana Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002214 flavonoid derivatives Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本申请涉及中药技术领域,具体而言,涉及一种治疗骨折的中药组合物及其制备方法。一方面,本申请提供一种治疗骨折的中药组合物,按重量份数计,其包括:三七2‑20份、红花2‑20份、桃仁2‑20份、重楼2‑20份、血竭1‑10份和麝香0.1‑1份。其费用低,无副作用,可大大缩短了骨折后的愈合时间,还能明显减轻患者骨折后的疼痛感。另一方面,本申请提供一种治疗骨折的中药组合物的制备方法,其能有效提取药物中的有效成分,利于人体吸收,且将各种药物制成片剂或丸剂,便于携带和服用。
Description
技术领域
本申请涉及中药技术领域,具体而言,涉及一种治疗骨折的中药组合物及其制备方法。
背景技术
骨折是指骨结构的连续性完全或部分断裂。多见于儿童及老年人,中青年人也时有发生。病人常为—个部位骨折,少数为多发性骨折。经及时恰当处理,多数病人能恢复原来的功能,少数病人可遗留有不同程度的后遗症。
一旦骨折发生,会引起全身或局部疼痛,骨折部位发生变形或断裂,需要及时救治。目前治疗骨折的方法多以手术治疗为主,其创伤大,愈合慢,患者痛苦大,且治疗费用较高,术后易产生并发症或后遗症。现有的中医治疗方法一般采用复位、内服中药以及外服药膏的方法,其疗效慢,效果差。
发明内容
本申请的目的在于提供一种治疗骨折的中药组合物,其费用低,无副作用,可大大缩短了骨折后的愈合时间,还能明显减轻患者骨折后的疼痛感。
本申请的另一目的在于提供一种治疗骨折的中药组合物的制备方法,其能有效提取药物中的有效成分,利于人体吸收,且将各种药物制成片剂或丸剂,便于携带和服用。
本申请解决其技术问题是采用以下技术方案来实现的。
一方面,本申请实施例提供一种治疗骨折的中药组合物,按重量份数计,其包括:三七2-20份、红花2-20份、桃仁2-20份、重楼2-20份、血竭1-10份和麝香0.1-1份。
另一方面,本申请实施例提供一种治疗骨折的中药组合物的制备方法,其包括以下步骤:
S1,将新鲜三七清洗、干燥、粉碎后得到粗粉,在粗粉中加入乙醇提取两次,过滤得滤液一和滤渣一;将滤渣一加水煎煮、过滤后浓缩,得三七提取液;
S2,将S1中的三七提取液通过大孔吸附树脂柱,先用蒸馏水去糖、色素,再以70%乙醇进行洗脱,得到洗脱液;将洗脱液和S1中的滤液一混合,回收乙醇,浓缩制得浸膏;
S3,将红花研磨,制得药粉一,在药粉一加入50-60vol%乙醇,振荡后将其放入超声仪中,工作30min-1h后取出得到提取液;对提取液抽滤、浓缩,得到提取物;
S4,将其余组分粉碎、研磨、混合,得到药粉二;
S5,将S2制得的浸膏、S3制得的提取物和S4制得的药粉二混合,制成片剂或丸剂。
相对于现有技术,本申请的实施例至少具有如下优点或有益效果:
1.本申请提供一种治疗骨折的中药组合物,按重量份数计,其包括:三七2-20份、红花2-20份、桃仁2-20份、重楼2-20份、血竭1-10份和麝香0.1-1份。其费用低,无副作用,以三七、红花、桃仁、重楼、血竭和麝香配伍,具有良好的止血功能和显著的造血功能,能扩张血管,改善微循环,血竭中的血竭素可大大缩短了骨折后的愈合时间,还能明显减轻患者骨折后的疼痛感。
2.本申请提供一种治疗骨折的中药组合物的制备方法,其包括:S1,将新鲜三七清洗、干燥、粉碎后得到粗粉,在粗粉中加入乙醇提取两次,过滤得滤液一和滤渣一;将滤渣一加水煎煮、过滤后浓缩,得三七提取液;S2,将S1中的三七提取液通过大孔吸附树脂柱,先用蒸馏水去糖、色素,再以70%乙醇进行洗脱,得到洗脱液;将洗脱液和S1中的滤液一混合,回收乙醇,浓缩制得浸膏,如此,能够有效提取三七中的有效成分;S3,将红花研磨,制得药粉一,在药粉一加入50-60vol%乙醇,振荡后将其放入超声仪中,工作30min-1h后取出得到提取液;对提取液抽滤、浓缩,得到提取物,该方法提取效率高;S4,将其余组分粉碎、研磨、混合,得到药粉二;S5,将S2制得的浸膏、S3制得的提取物和S4制得的药粉二混合,制成片剂或丸剂。该方法将三七制成浸膏、将红花制成提取液、将其与药粉制成粉末,无需添加其他粘合剂,其能有效提取药物中的有效成分,利于人体吸收,且将各种药物制成片剂或丸剂,便于携带和服用。
具体实施方式
为使本申请实施例的目的、技术方案和优点更加清楚,下面将对本申请实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。下面将参考具体实施例来详细说明本申请。
一方面,本申请提供一种治疗骨折的中药组合物,按重量份数计,其包括:三七2-20份、红花2-20份、桃仁2-20份、重楼2-20份、血竭1-10份和麝香0.1-1份。
三七,为五加科植物三七的干燥根。其味甘、微苦,性温。具有化瘀止血,活血定痛的功效。主治出血症,跌打损伤,瘀血肿痛。三七被人们誉为“人参之王”,其总皂甙含量约为12vol%,是三七主要药理活性成分;其中的黄酮类化合物是三七有效活性成分。三七黄酮可以分离出槲皮素,大量药理研究表明槲皮素具有祛痰、镇咳、平喘、降压、强心、增加冠脉流量、降血脂、增强肾上腺素、增加毛细血管抵抗力和降低毛细血管渗透性的作用。三七含有单糖、鼠李糖、木糖、葡萄糖以及低聚糖和多糖。多糖往往具有生理活性,部分多糖具有提高机体免疫功能和抗肿瘤活性。研究表明,从三七中分离的三七多糖A和三七茎叶多糖,可以增强有机体免疫能力,促进巨噬细胞和抗体分泌细胞活性,对自然杀伤细胞和抗原结合细胞无明显影响。三七中的三七素具有非常好的止血功能,并且相比于人参、西洋参等,三七中的三七素含量最高。三七中还含有18种以上的微量元素。综上,三七具有以下功效:(1)良好的止血功效和显著的造血功能;(2)能加强和改善冠脉微循环,扩张血管;(3)具有较强的镇痛、抗炎作用;(4)具有免疫调节剂的作用,能使过高或过低的免疫反应恢复到正常,但不干扰机体正常的免疫反应;(5)具有抗肿瘤、抗衰老、抗氧化作用。
红花,为菊科植物红花的干燥花。其味辛,性温。具有活血通经,散瘀止痛之功效。用于经闭,痛经,恶露不行,症瘕痞块,胸痹心痛,瘀滞腹痛,胸胁刺痛,跌扑损伤,疮疡肿痛。其化学成分有黄铜、亚精胺、木脂素等。现代药理学研究表明,红花有扩张血管、增加血流量、改善微循环和抑制血小板聚集等作用,对脑梗塞动物的脑组织有保护作用,同时具有抗炎镇痛、抗肿瘤、抗菌和抗疲劳作用。
桃仁,为蔷薇科植物桃或山桃的干燥成熟种子。其为苦、甘,性平。具有活血祛瘀,润肠通便,止咳平喘的功效。用于经闭痛经,症瘕痞块,肺痈肠痈,跌扑损伤,肠燥便秘,咳嗽气喘。桃仁含苦杏仁苷、24-亚甲基环木菠萝烷醇、野樱苷、β-谷甾醇和菜油甾醇及它们的葡萄糖苷等,还含绿原酸、3-咖啡酰奎宁酸、苦杏仁酶、挥发油及脂肪油。其煎剂有抗炎作用,所含脂肪油有润肠缓下作用,提取物有扩张血管作用。醇提取物有抑制血液凝固作用。桃仁还可抗过敏、镇咳、镇痛,促进初产妇子宫收缩、止血等。
重楼,为百合科植物云南重楼或七叶一枝花的干燥根茎。其味苦,性微寒;有小毒。具有清热解毒,消肿止痛,凉肝定惊之功效,常用于疔疮痈肿,咽喉肿痛,蛇虫咬伤,跌扑伤痛,惊风抽搐。
血竭,为棕榈科植物麒麟竭果实渗出的树脂经加工制成,系传统名贵中药。其味甘、咸,性平。具有活血定痛,化瘀止血,生肌敛疮的功效。用于跌打损伤,心腹瘀痛,外伤出血,疮疡不敛。现代药理学证实其具有抗氧化、活血止血、改善脂质代谢、改善机体微循环等多种生理活性,目前临床上多用于伤科技消化道出血。血竭成分复杂,多为黄酮类衍生物、挥发油、酚类及甾体化合物。血竭作为“活血圣药”,具有良好的活血功效,可抑制血栓形成,同时具备收敛止血的双向调节作用。
皮肤创伤愈合主要包炎症反应阶段、组织细胞增生阶段和组织重塑阶段,各阶段的特征体现为肉芽组织形成、表皮再上皮化、血管再生。其中,肉芽组织填充是创面愈合的关键步骤,成纤维细胞增殖分化则是肉芽组织增生的关键。血竭素高氯酸盐可以通过促进纤维细胞的增殖,进而促进大鼠皮肤创面愈合,促进创面愈合在早期形成较为成熟的Ⅰ型胶原,提高愈合质量,而在完全愈合后减少Ш型胶原的形成,抑制过度修复造成的病理性瘢痕,具有双向调节作用。此外,血竭可促进血管内皮生长因子表达,调节血管通透性,加速血管内皮细胞迁移,促进血管形成,提高组织供氧,加快创面愈合。
麝香,为鹿科动物林麝、马麝或原麝成熟雄体香囊中的干燥分泌物。其味辛,性温。具有开窍醒神,活血通经,消肿止痛的功效。主治闭证神昏,疮疡肿毒,瘰疬痰核,咽喉肿痛,血瘀经闭,症瘕,心腹暴痛,头痛,跌打损伤,风寒湿痹,难产,死胎,胞衣不下。麝香中的多肽类蛋白具有抗炎作用。麝香水溶性蛋白对体液免疫和细胞免疫有增强作用。
需要说明的是,本申请中的麝香也可以用人工麝香代替。
在本申请的一些实施例中,按重量份数计,其包括三七10份、红花5份、桃仁5份、重楼5份、血竭5份和麝香0.5份。
该配比的组合物剂量适中,不会因剂量过大产生毒性,也不会因剂量不够影响药效,适合成人使用,小儿酌情减少用量。
在本申请的一些实施例中,按重量份数计,还可以包括:土元2-20份、大伸筋2-20份、续断2-10份。
土元,地鳖蠊科昆虫地鳖或冀地鳖的雌虫干燥体。捕捉后,置沸水中烫死,晒干或烘干。其性寒,味咸,临床上多用于治疗身体出现的产后瘀血、腹痛、跌打损伤、木舌、重舌等临床疾病。此外,土元对于恶性肿瘤和传染性疾病都有一定的治疗效果,比如肺癌、乳腺癌、白血病、乙型肝炎、肝硬化、脑血管病、脑梗塞等。
大伸筋,为木兰科五味子属的草本植物。其性温,味涩。具有温经活络,健胃利湿的功效。用于治疗风湿,跌打,胃痛,月经不调,肾炎。
续断,为川续断科多年生草本植物川续断的干燥根,因能“续折接骨”而得名。其性微温,味苦、辛;归肝、肾经。有补肝肾、强筋骨、续折伤、止崩漏的功效,可用于治疗肝肾不足、腰膝酸软、风湿痹痛、筋伤骨折、崩漏、胎漏、跌扑损伤等病症。其中酒续断多用于风湿痹痛、筋伤骨折、跌扑损伤,盐续断多用于腰膝酸软。续断辛温破散之性,善能活血祛瘀;甘温补益之功,又能壮骨强筋,而有续筋接骨、疗伤止痛之能。用治跌打损伤,瘀血肿痛,筋伤骨折。常与桃仁、红花、穿山甲、苏木等配伍同用;或与当归、木瓜、黄芪等同用,治疗脚膝折损愈后失补,筋缩疼痛。
在本申请的一些实施例中,按重量份数计,还可以包括益母草2-10份、羌活2-10份和延胡索2-10份。
益母草,为唇形科植物益母草的新鲜或干燥地上部分。其味苦、辛,性微寒。具有活血调经,利尿消肿,清热解毒之功效。用于月经不调,痛经经闭,恶露不尽,水肿尿少,疮疡肿毒。
羌活,伞形科植物羌活的干燥根。其味辛、苦,性温。具有解表散寒,祛风胜湿,止痛的功效。用于治疗风寒感冒,风寒湿痹,项强筋急,骨节酸疼,风水浮肿,痈疽疮毒。
延胡索,是罂粟科、紫堇属多年生草本植物。延胡索以块茎入药,有活血散淤、利气止痛的功能,主治心腹腰膝疼痛、跌打损伤、淤血作痛、月经不调等症,是一味传统的止痛药。
三七、红花、桃仁和麝香协同具有良好的止血功能和显著的造血功能,能扩张血管,改善微循环。重楼可消肿止痛,与血竭配伍更能够调节血管通透性,促进创面愈合,对于骨折患者疗效甚好。土元、大伸筋和续断配伍,具有舒筋活血、活血散瘀的功效,益母草、羌活和延胡索配伍,镇痛作用好,能大大减轻患者的痛苦。该组合配伍优良,用量适中,具有最佳的疗效。
另一方面,本申请提供一种治疗骨折的中药组合物的制备方法,其包括:
S1,将新鲜三七清洗、干燥、粉碎后得到粗粉,在粗粉中加入乙醇提取两次,过滤得滤液一和滤渣一;将滤渣一加水煎煮、过滤后浓缩,得三七提取液;
S2,将S1中的三七提取液通过大孔吸附树脂柱,先用蒸馏水去糖、色素,再以70%乙醇进行洗脱,得到洗脱液;将洗脱液和S1中的滤液一混合,回收乙醇,浓缩制得浸膏;
S3,将红花研磨,制得药粉一,在药粉一加入50-60vol%乙醇,振荡后将其放入超声仪中,工作30min-1h后取出得到提取液;对提取液抽滤、浓缩,得到提取物;
S4,将其余组分粉碎、研磨、混合,得到药粉二;
S5,将S2制得的浸膏、S3制得的提取物和S4制得的药粉二混合,制成片剂或丸剂。
本申请中,为了保证三七的提取效率,将滤渣一再加水煎煮,在通过树脂提取,提取效率更高。该制备方法对三七和红花中的有效成分进行提取,具有较好地提取效率,再与其他药粉混合制成片剂或丸剂,方便携带和服用。
在本申请的一些实施例中,S1中,乙醇的浓度60-70vol%。乙醇浓度为60-70vol%时,可抑制提取过程中一些菌类物质的生长,抑菌效果较好,对药物中有效成分的浸出率也较高。
在本申请的一些实施例中,S2中,洗脱流速为1.5-2.0mL/min。在上述洗脱流速下,能够较好地洗脱出残留的乙醇,且不会将三七中的有效成分洗脱掉。
在本申请的一些实施例中,S3中,药粉一和乙醇的比例为1g:10-15ml。在上述比例下,对红花中有效成分的提取效率更高。
在本申请的一些实施例中,在S3中,超声仪的超声功率为700-800W。上述超声功率能增加提取效率,并且抑菌效果好。
在本申请的一些实施例中,在S5中,片剂或丸剂的含水量小于1wt%。含水量小于1wt%时,片剂或丸剂的保质期更长。
以下结合实施例对本申请的特征和性能作进一步的详细描述。
实施例
根据表1中的成分准备原料。
表1实施例1-9中各原料的配比
实施例1-2中的中药组合物的制备方法如下:
三七浸膏的制备:将新鲜三七清洗、干燥、粉碎后得到粗粉,在粗粉中加入60vol%乙醇提取两次,过滤得滤液一和滤渣一;将滤渣一加水煎煮、过滤后浓缩,得三七提取液;将三七提取液通过大孔吸附树脂柱,先用蒸馏水去糖、色素,再以70vol%乙醇进行洗脱,洗脱得到洗脱液,洗脱流速为1.5mL/min;将洗脱液和滤液一混合,回收乙醇,浓缩制得浸膏。
红花提取物的制备:将红花研磨,制得药粉一,在药粉一加入50vol%乙醇,药粉一与乙醇的比例为1g:10mL,振荡后将其放入超声仪中,超声功率为700W,工作30min后取出得到提取液;对提取液抽滤、浓缩,得到红花提取物。
将其余组分分别粉碎、研磨、混合,得到药粉二;将三七浸膏、红花提取物和药粉二混合,制成含水量小于1wt%的片剂。
实施例3-4中的中药组合物的制备方法如下:
三七浸膏的制备:将新鲜三七清洗、干燥、粉碎后得到粗粉,在粗粉中加入65vol%乙醇提取两次,过滤得滤液一和滤渣一;将滤渣一加水煎煮、过滤后浓缩,得三七提取液;将三七提取液通过大孔吸附树脂柱,先用蒸馏水去糖、色素,再以70vol%乙醇进行洗脱,洗脱得到洗脱液,洗脱流速为2mL/min;将洗脱液和滤液一混合,回收乙醇,浓缩制得浸膏。
红花提取物的制备:将红花研磨,制得药粉一,在药粉一加入60vol%乙醇,药粉一与乙醇的比例为1g:12mL,振荡后将其放入超声仪中,超声功率为800W,工作45min后取出得到提取液;对提取液抽滤、浓缩,得到红花提取物。
将其余组分分别粉碎、研磨、混合,得到药粉二;将三七浸膏、红花提取物和药粉二混合,制成含水量小于1wt%的丸剂。
实施例5-6中的中药组合物的制备方法如下:
三七浸膏的制备:将新鲜三七清洗、干燥、粉碎后得到粗粉,在粗粉中加入65vol%乙醇提取两次,过滤得滤液一和滤渣一;将滤渣一加水煎煮、过滤后浓缩,得三七提取液;将三七提取液通过大孔吸附树脂柱,先用蒸馏水去糖、色素,再以70%乙醇进行洗脱,洗脱得到洗脱液,洗脱流速为2mL/min;将洗脱液和滤液一混合,回收乙醇,浓缩制得浸膏。
红花提取物的制备:将红花研磨,制得药粉一,在药粉一加入60vol%乙醇,药粉一与乙醇的比例为1g:12mL,振荡后将其放入超声仪中,超声功率为800W,工作45min后取出得到提取液;对提取液抽滤、浓缩,得到红花提取物。
将其余组分分别粉碎、研磨、混合,得到药粉二;将三七浸膏、红花提取物和药粉二混合,制成含水量小于1wt%的丸剂。
实施例7-10中的中药组合物的制备方法如下:
三七浸膏的制备:将新鲜三七清洗、干燥、粉碎后得到粗粉,在粗粉中加入65vol%乙醇提取两次,过滤得滤液一和滤渣一;将滤渣一加水煎煮、过滤后浓缩,得三七提取液;将三七提取液通过大孔吸附树脂柱,先用蒸馏水去糖、色素,再以70vol%乙醇进行洗脱,洗脱得到洗脱液,洗脱流速为2mL/min;将洗脱液和滤液一混合,回收乙醇,浓缩制得浸膏。
红花提取物的制备:将红花研磨,制得药粉一,在药粉一加入70vol%乙醇,药粉一与乙醇的比例为1g:15mL,振荡后将其放入超声仪中,超声功率为750W,工作1h后取出得到提取液;对提取液抽滤、浓缩,得到红花提取物。
将其余组分分别粉碎、研磨、混合,得到药粉二;将三七浸膏、红花提取物和药粉二混合,制成含水量小于1wt%的片剂。
效果例
本申请提供的一种治疗骨折的中药组合物的服用方法如下:
每次1-3克,每天服用两次。
病例一,张某。男,48岁。不小心从凳子上滑下来,右脚跖骨第2、3、4骨折。经医院检查,需要做钢针内固定手术。服用实施例10中的中药组合物三个周后,到医院X线检查。骨折线已经模糊,走路完全不受影响,并且无肿胀疼痛,基本愈合。
病例二,陈某,男,65岁。不慎滑倒后右手掌着地,造成右手科累氏骨折。经手法复位小夹板固定后,服用实施例6中的中药组合物三个周后,功能活动不受任何影响。X线检查,骨折线模糊,明显能看到骨痂形成。手的握力基本恢复。约在服药十天后吃饭、端杯就能完成。
病例三,陈某,男,13岁。因滑旱冰摔倒后致右股骨劲骨折。经医院钢钉内固定,术后三个月出现髋骨疼痛。复查显示股骨头坏死。服用实施例6提供的中药组合物两个月后复查,发现X线片,股骨头开始生长。塌陷的股骨头明显变圆,骨质开始沉着。并且在服药三天后疼痛消失。
病例四:徐某,女,70岁。不小心摔倒后致腰疼。经医院检查,诊断为腰椎四五压缩性骨折,患者腰痛难忍。医院建议内固定。因患者年龄大,手术有一定风险。服用实施例4提供的中药组合物五天后腰疼消失,能在床上翻身。一个月后,下床能自主活动,站立行走无疼痛,经X线检查压缩部位较受伤时明显改善。继续服用一个月后,恢复正常。
综上所述,本申请实施例提供一种治疗骨折的中药组合物,以三七、红花、桃仁和麝香配伍,三七具有良好的止血功能和显著的造血功能,红花和桃仁能扩张血管,改善微循环。重楼可消肿止痛,与血竭配伍能够调节血管通透性,促进创面愈合,对于骨折患者疗效甚好。土元、大伸筋和续断配伍,具有舒筋活血、活血散瘀的功效,益母草、羌活和延胡索配伍,镇痛作用好,能大大减轻患者的痛苦。该组合配伍优良,用量适中,具有最佳的疗效。
以上所描述的实施例是本申请一部分实施例,而不是全部的实施例。本申请的实施例的详细描述并非旨在限制要求保护的本申请的范围,而是仅仅表示本申请的选定实施例。基于本申请中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本申请保护的范围。
Claims (10)
1.一种治疗骨折的中药组合物,其特征在于,按重量份数计,其包括:三七2-20份、红花2-20份、桃仁2-20份、重楼2-20份、血竭1-10份和麝香0.1-1份。
2.根据权利要求1所述的治疗骨折的中药组合物,其特征在于,按重量份数计,其包括三七10份、红花5份、桃仁5份、重楼5份、血竭5份和麝香0.5份。
3.根据权利要求1所述的治疗骨折的中药组合物,其特征在于,按重量份数计,还包括:土元2-20份、大伸筋2-20份、续断2-10份。
4.根据权利要求1所述的治疗骨折的中药组合物,其特征在于,按重量份数计,还包括益母草2-10份、羌活2-10份和延胡索2-10份。
5.一种如权利要求1-4任一项所述的治疗骨折的中药组合物的制备方法,其特征在于,其包括:
S1,将新鲜三七清洗、干燥、粉碎后得到粗粉,在粗粉中加入乙醇提取两次,过滤得滤液一和滤渣一;将滤渣一加水煎煮、过滤后浓缩,得三七提取液;
S2,将S1中的三七提取液通过大孔吸附树脂柱,先用蒸馏水去糖、色素,再以70%乙醇进行洗脱,得到洗脱液;将洗脱液和S1中的滤液一混合,回收乙醇,浓缩制得浸膏;
S3,将红花研磨,制得药粉一,在药粉一加入50-60vol%乙醇,振荡后将其放入超声仪中,工作30min-1h后取出得到提取液;对提取液抽滤、浓缩,得到提取物;
S4,将其余组分粉碎、研磨、混合,得到药粉二;
S5,将S2制得的浸膏、S3制得的提取物和S4制得的药粉二混合,制成片剂或丸剂。
6.根据权利要求5所述的治疗骨折的中药组合物的制备方法,其特征在于,所述S1中,所述乙醇的浓度60-70vol%。
7.根据权利要求5所述的治疗骨折的中药组合物的制备方法,其特征在于,所述S2中,所述洗脱流速为1.5-2.0mL/min。
8.根据权利要求5所述的治疗骨折的中药组合物的制备方法,其特征在于,所述S3中,所述药粉一和所述乙醇的比例为1g:10-15ml。
9.根据权利要求5所述的治疗骨折的中药组合物的制备方法,其特征在于,所述S3中,所述超声仪的超声功率为700-800W。
10.根据权利要求6所述的治疗骨折的中药组合物的制备方法,其特征在于,在S5中,所述片剂或丸剂的含水量小于1wt%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210273655.0A CN114588226A (zh) | 2022-03-19 | 2022-03-19 | 一种治疗骨折的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210273655.0A CN114588226A (zh) | 2022-03-19 | 2022-03-19 | 一种治疗骨折的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114588226A true CN114588226A (zh) | 2022-06-07 |
Family
ID=81810039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210273655.0A Pending CN114588226A (zh) | 2022-03-19 | 2022-03-19 | 一种治疗骨折的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114588226A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102370834A (zh) * | 2010-08-16 | 2012-03-14 | 王安财 | 接骨散 |
-
2022
- 2022-03-19 CN CN202210273655.0A patent/CN114588226A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102370834A (zh) * | 2010-08-16 | 2012-03-14 | 王安财 | 接骨散 |
Non-Patent Citations (1)
Title |
---|
孙超等: "中药接骨膏的研制及药物机理", 《承德医学院学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100402081C (zh) | 治疗妇科疾病的中成药及其制备方法 | |
CN103463297B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法和用途 | |
CN104815295A (zh) | 一种治疗颈椎病的中药制剂 | |
CN103877247B (zh) | 用于治疗褥疮的药物及其制备方法 | |
CN102772712B (zh) | 一种治疗热毒炽盛血瘀型糖尿病足的中药组合物 | |
CN105250619A (zh) | 一种治疗内在性子宫内膜异位症的中药及其制备方法 | |
CN102552608B (zh) | 一种治疗骨折、骨损伤的药物组合物及其制备方法和用途 | |
CN103933405A (zh) | 用于治疗气血两虚型烧伤的药物组合物及其制备方法 | |
CN103736017A (zh) | 一种治疗肋间神经痛的中药组合物及其制备方法 | |
CN105709074A (zh) | 一种治疗风湿性关节炎及骨质增生的药物及制备方法 | |
CN105232987A (zh) | 一种促进神经外科术后康复的中药 | |
CN105194338A (zh) | 一种治疗宫寒的中药组合物及其制备方法 | |
CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
CN106266109A (zh) | 一种治疗泌尿系统结石的中药组合物及其制备方法 | |
CN114588226A (zh) | 一种治疗骨折的中药组合物及其制备方法 | |
CN105169265A (zh) | 一种治疗偏瘫的中药组合物及其制备方法 | |
CN104623615A (zh) | 一种治疗哮喘的药物 | |
CN104338052A (zh) | 治疗脑血栓的中药配方 | |
CN109771567A (zh) | 一种中草药扶正化瘀排毒化肿瘤的配方 | |
CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
CN105362944A (zh) | 一种治疗骨科扭挫伤的中药膏剂 | |
CN105664022A (zh) | 一种治疗子宫癌的中药组合物制剂及其制备方法 | |
CN104997881A (zh) | 一种可治疗增生性脊椎炎的汤剂药物及其制备方法 | |
CN104666922A (zh) | 一种治疗脾肾气虚型月经不调的中药组合物 | |
CN103933359A (zh) | 用于祛除瘢痕疙瘩的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220607 |